Clinical trial · Interventional
Effect of Yong Chong Cao Capsule on Outcomes in Patients With Mild to Severe COPD
A Multi-center, Open-label, Randomized, Controlled Study to Evaluate the Effectiveness of Yong Chong Cao Capsule on Outcomes in Patients With Mild to Severe COPD
NCT03745261CI-TRIAL-00035863unknownPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this study is to evaluate the effectiveness of Yong Chong Cao capsule on outcomes in patients with mild to severe Chronic Obstructive Pulmonary Disease (COPD).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pulmonary Disease, Chronic Obstructive | — | UNRESOLVED | — |
Interventions
Interventions (5)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| BL capsule | Drug | — | UNRESOLVED |
| Salbutamol (Ventolin®) | Drug | — | UNRESOLVED |
| Salmeterol / fluticasone (Seretide®) | Drug | — | UNRESOLVED |
| Tiotropium Bromide (Spiriva®) | Drug | — | UNRESOLVED |
| YCC capsule | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- YCC capsule+conventional medicine
- description
- Patients in this group will be given Yong Chong Cao (YCC) capsule and conventional medicine based on the classes of medications recommended by 2017 GOLD and Chinese Treatment Guidelines for COPD,which are Group A patients: Salbutamol (Ventolin®),Group B and Group C patients: Tiotropium Bromide (Spiriva®),Group D patients: Salmeterol / fluticasone (Seretide®).
- interventionNames
- Drug: Salbutamol (Ventolin®)
- Drug: Tiotropium Bromide (Spiriva®)
- Drug: Salmeterol / fluticasone (Seretide®)
- Drug: YCC capsule
- type
- EXPERIMENTAL
- label
- BL capsule + conventional medicine
- description
- Patients in this group will be given Bailing (BL) capsule and conventional medicine based on the classes of medications recommended by 2017 GOLD and Chinese Treatment Guidelines for COPD, which are Group A patients: Salbutamol (Ventolin®),Group B and Group C patients: Tiotropium Bromide (Spiriva®),Group D patients: Salmeterol / fluticasone (Seretide®).
- interventionNames
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * A confirmed diagnosis of mild to severe COPD. * Medically stable. * Syndrome differentiation belongs to syndrome of insufficiency of qi of the lung and kidney. * Age between 18 and 80 years. * With the informed consent signed. Exclusion Criteria: * Pregnant or breast-feeding women. * Current respiratory disorders other than COPD (e.g., bronchiectasis, bronchial asthma, tuberculosis, lung fibrosis, pulmonary thromboembolic, diffuse panbronchiolitis, lung cancer). * Complicated with heart failure (NYHA Class III or IV), or myocardial infarction within six months ,or unstable hemodynamics. * Complicated with serious hepatic and renal diseases (liver cirrhosis, portal hypertension, bleeding of varicose veins, dialysis, or renal transplantation). * Any psychiatric condition rendering the patient unable to understand the nature, scope and possible consequences of the study. * Participating in other trials or allergic to the used medicine. * Participating in other clinical trials with other interventions in one month. * Allergic to the used medicine.
References
Publications (1)
- DERIVEDLi S, Xie Y, Lin L, Wu L, Yu X, Ma Z, Yin Q. The Effectiveness of Yong Chong Cao Capsule in Patients With Mild to Severe COPD: A Multi-Center, Randomized, Active-Controlled Trial. J Evid Based Med. 2025 Dec;18(4):e70091. doi: 10.1111/jebm.70091. Epub 2025 Nov 26. PMID 41295088